Health BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM… James Pereira Jul 15, 2023 PALO ALTO, Calif., July 14, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a… Read More...
Health Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership… James Pereira Jul 13, 2023 – Project ‘NADER’ is intended to span multiple phases, starting from mapping rare diseases in the UAE and wider region… Read More...
Health BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated… James Pereira Mar 18, 2023 <!-- Name:DistributionId Value:8790244 --> <!--… Read More...
Health BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant… James Pereira Dec 23, 2022 - The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects… Read More...
Health BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular… James Pereira Oct 14, 2022 Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i,… Read More...
Health BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy… James Pereira Oct 14, 2022 - Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic… Read More...
Health BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a… James Pereira Jun 27, 2022 – BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold… Read More...
Health BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of… James Pereira May 26, 2022 - BBP-671 detected in healthy volunteer plasma and cerebrospinal fluid (CSF), suggesting that BBP-671 is entering the… Read More...
Health BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers… James Pereira May 14, 2022 -Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in… Read More...
Health BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in… James Pereira Apr 3, 2022 - NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or… Read More...